Logo www.CancerITIM.org
Slogan
   


     
 

  5th International

CANCER IMMUNOTHERAPY & IMMUNOMONITORING

Conference

CITIM-2017

 

 

April 24-27, 2017

 

Prague, Czech Republic


 

 

Topics to be discussed:

 

 

Inflammation and immunity in the tumor microenvironment

 

Regulatory and effector mechanisms in the tumor immunoenvironment  

 

Tumor microenvironment and cancer immunotherapy

 

Preclinical models of cancer immunotherapy

 

Cancer immunotherapy : Clinical trials 

 

Cancer immunotherapy: Regulatory cells and cytokines

 

Cancer immunotherapy: New approaches

 

Cancer biomarkers and immunomonitoring in cancer clinical trials

 

PROGRAM




CITIM-2017 PROGRAM

Prague, Czech Rep             April 24-27, 2017

 

 

April 24, 2017

 

 

Registration                                                    13:30 – 18:30                         

 

 

Conference opening ceremony       14:00 – 14:30

                       

Conference opening 

Michael R. Shurin (Chair, CITIM Organizing Committee)

Greetings (Cancer Microenvironment Society (ICMS), Association for Cancer Immunotherapy (CIMT), PIVAC, Israeli Society for Cancer Research, ENCI (European Network Cancer Immunotherapy), Czech Immunological Society (CIS))

Welcome remarks and Information

            Luca Vannucci (Chair, Local Organizing Committee)

Blanka Říhová (President of the Czech Immunological Society)

Viktor Umansky (CITIM Organizing Committee)

 

 

KEYNOTE LECTURE                                                            14:30 – 15:30

 

Chair: Viktor Umansky (Heidelberg, Germany)

Giorgio Trinchieri

NIH Distinguished Investigator

Director, Cancer and Inflammation Program

Center for Cancer Research, NCI, NIH

Associate Director for Basic Science

Trans-NIH Center for human Immunology

Bethesda, Maryland, USA

 

Cancer as a disease of the symbiont/metaorganism

 

____________________________________

 

 

PLENARY SESSION 1                                                           15:40 – 17:40

Immunity and the malignant process I

Chair: Dmitry Gabrilovich (Philadelphia, PA, USA)

Chair: Blanka Říhová (Prague, Czech Rep)

 

 

Isaac Witz (Tel Aviv, Israel)                                                    15:40 - 16:10

The metastatic microenvironment: Tumor-associated and microenvironmental drivers of metastasis

 

Sven Brandau (Essen, Germany)                                          16:10 - 16:40

Novel functions of toll-like receptors in tumor immunity

 

Suzanne Ostrand-Rosenberg (Baltimore, MD, USA)           16:40 - 17:10  

High fat diet and leptin drive myeloid-derived suppressor cells (MDSC) that protect against metabolic dysfunction, but promote tumor progression

 

Paul Lehmann (Cleveland, OH, USA)                                   17:10 - 17:40

The natural history of autoreactive (tumor reactive?) T cells

 

 

Coffee break                                                               17:40 – 18:00

 

 

PLENARY SESSION 2                                                           18:00 – 19:35

Immunity and the malignant process II

Chair: Michal Baniyash (Jerusalem, Israel)

Chair: Kelvin Lee (Buffalo, NY, USA)

 

Elena Voronov (Beer Sheva, Israel)                                      18:00 – 18:25

A dual effect of IL-1 alpha in colon inflammation and inflammation-related colon cancer

 

Dmitriy W. Gutkin (Pittsburgh, PA, USA)                              18:25 – 18:45

Immune infiltrate in premalignant lesions

 

Natalia Aptsiauri (Granada, Spain)                                       18:45 – 19:05

Correlation between HLA class I and PD-L1/PD1 expression in human tumors

 

Nathan Karin (Haifa, Israel)                                                   19:05 – 19:35

The role of chemokines in regulating tumor immunity 

 

____________________________________

 

 

Welcome reception, Hotel Ambassador         19:45 – 22:00

 

 

 


April 25, 2017

 

Keynote Presentation                                                           8:20 – 9:05

 

Chair: Arthur Hurwitz (Lexington, MA, USA)

 

Rolf Kiessling (Stockholm, Sweden)

Counteracting tumor induced immune suppression

 

 

PLENARY SESSION 3                                                           9:05 – 10:55

Regulatory pathways in the tumor immunoenvironment I

 

Chair: Viktor Umansky (Heidelberg, Germany)

Chair: Joost J. Oppenheim (Frederick, MD, USA)

 

Federico Garrido (Granada, Spain)                                      9:05 - 9:35

Rejection versus escape: The tumour MHC dilemma

 

Dmitry I. Gabrilovich (Philadelphia, PA, USA)                      9:35 - 10:05

Regulation of myeloid cell differentiation in cancer

 

 

SPECIAL SUBSESSION

The Peripheral Nervous System in the tumor microenvironment

 

Anton A. Keskinov (Pittsburgh, PA, USA)                            10:05 - 10:20

Sensory neurons and the tumor immunoenvironment

 

Yuri Bunimovich (Pittsburgh, PA, USA)                                10:20 - 10:35

Neuroglial support of the melanoma microenvironment

 

Michael R. Shurin (Pittsburgh, PA, USA)                              10:35 - 10:55

Cancer-PNS-Immune axis: New concept and new data

 

 

Coffee break                                                   10:55 – 11:15 

 

 

PLENARY SESSION 4                                                           11:15 – 13:25

Regulatory pathways in the tumor immunoenvironment II

                                                                       

     Chair: Isaac Witz (Tel Aviv, Israel)

     Chair: Lenka Zdrazilova-Dubska (Brno, Czech Rep)

 

Zvi G. Fridlender (Jerusalem, Israel)                         11:15 - 11:40

Tumor related neutrophils - important modulators of the immune reaction to cancer

 

Viktor Umansky (Heidelberg, Germany)                               11:40 - 12:05

Immunoregulatory circuits in the melanoma microenvironment

 

Adit Ben-Baruch (Tel Aviv, Israel)                                       12:05 - 12:35

Inflammation-driven tumor-stroma interactions in breast cancer

 

Jonathan Weiss (Frederick, MD, USA)                                 12:35 - 12:55

Crosstalk between macrophage metabolism and tumor progression

 

Blanka Říhová (Prague, Czech Rep)                        12:55 - 13:25

Polymeric prodrugs act as endogeneous vaccines

 

Lunch break                                                    13:25 – 14:20

 

 

PLENARY SESSION 5                                                           14:20 – 16:40

Regulatory pathways in the tumor immunoenvironment III

 

       Chair: Suzanne Ostrand-Rosenberg (Baltimore, MD, USA)

       Chair: Graham Pawelec (Tübingen, Germany)

 

Michal Baniyash (Jerusalem, Israel)                         14:20 - 14:50

The plasticity of myeloid-derived suppressor cells: Clinical implications

 

Kelvin Lee (Buffalo, NY, USA)                                               14:50 - 15:20

Food and shelter and cancer progression

 

Salem Chouaib (Villejuif, France)                                        15:20 - 15:50

Regulation of immune resistance and immune suppression by hypoxia

 

Lenka Zdrazilova-Dubska (Brno, Czech Rep)                      15:50 - 16:10

Immunomonitoring of patients treated by cancer immunotherapy: rationale and showcases

 

Udo Gaipl (Erlangen, Germany)                                            16:10 - 16:40

Immune modulatory properties of radiotherapy - rationales for combination with immunotherapy

 

 

Coffee break                                                   16:40 – 17:20 

 

 

POSTER SESSION                                                                16:40 – 17:55

 

__________________________________________________________

 

 

Prague overview sightseeing walking tour for CITIM-2017 participants      18:00 – 20:00

 

 

 


April 26, 2017

 

Keynote Presentation                                                           8:30 – 9:15

 

Chair: Natalia Aptsiauri (Granada, Spain)

 

Graham Pawelec (Tübingen, Germany)

Immune signatures predicting responses to immunomodulatory antibody therapy

 

 

PLENARY SESSION 6                                                           9:20 – 11:20

Inflammation, microbiota and cancer: regulatory mechanisms

 

                                                                                    Chair: Jay A. Berzofsky (Bethesda, MD, USA)

Chair: Catherine Sautes-Fridman (Paris, France)

 

Ron Apte (Beer-Sheva, Israel)                                               9:20 – 9:45

The microenvironment shifts the balance between inflammation and immunity in tumors

 

Janko Kos (Ljubljana, Slovenia)                                            9:45 – 10:05

Cystatin F dependent regulation of NK and T cell cytotoxicity

 

Miloslav Kverka (Prague, Czech Rep)                                  10:05 – 10:25

Diet and microbiota as modulators of gut inflammation and colon cancer

 

Anahid Jewett (Los Angeles, CA, USA)                                10:25 – 10:50

Systemic regulation of super-charged NK cell function by intestinal microflora in BLT humanized mice leads to lysis, growth inhibition and balanced differentiation of Cancer Stem Cells

 

Luca Vannucci (Prague, Czech Rep)                                    10:50 – 11:15

Stroma and immunity cross-talk build the tumor microenvironment

 

Mathias Chamaillard (Lille, France)                                      11:15 – 11:35

Remote control of intestinal tumorigenesis by the gut microbiota

 

 

Coffee break                                                   11:35 – 11:50

 

 

PLENARY SESSION 7                                                           11:50 – 14:10

Cancer immunotherapy I: New concepts and clinical data

 

Chair: Esteban Celis (Augusta, GA, USA)

Chair: Eitan Yefenof (Jerusalem, Israel)

 

Jay A. Berzofsky (Bethesda, MD, USA)                                11:50 – 12:20

Cancer Vaccine Strategies: Translation from mice to human clinical trials

 

Wolf H. Fridman (Paris, France)                                            12:20 – 12:50

Integration of molecular and immune classifications in human cancers: a guide for immunotherapies

 

Gurkamal S. Chatta (Buffalo, NY, USA)                                12:50 – 13:15

Chemokine modulation in Genito-urinary malignancies

 

Yulia Nefedova (Philadelphia, PA, USA)                               13:15 – 13:35

Regulation of tumor cell survival by myeloid cells in the bone marrow microenvironment

 

Thomas Sayers (Frederick, MD, USA)                                  13:35 – 14:00

Sensitization of melanoma cells to caspase-8-dependent cell death by specific 17beta-hydroxywithanolides

 

 

Lunch break                                                    14:00 – 14:50

 

 

PLENARY SESSION 8                                                           14:50 – 16:40

Cancer immunotherapy II: New targets and models

 

Chair: Wolf Fridman (Paris, France)

Chair: Per thor Straten (Herlev, Denmark)

 

Yasmin Thanavala (Buffalo, NY, USA)                                 14:50 – 15:10

Immunosuppressive pathways in HCC patients and beneficial immunomodulation following sorafenib therapy

 

Esteban Celis (Augusta, GA, USA)                                       15:10 – 15:35

Peptide vaccines for cancer can be effective, when used properly

 

Dmitri Loukinov (Rockville, MD, USA)                                  15:35 – 15:55

BORIS molecule is an attractive target for efficient immunotherapy of cancer

 

Arthur Hurwitz (Lexington, MA, USA)                                   15:55 – 16:20

Enhancing T cell responses to promote more durable tumor immunity

 

Benjamin Sredni (Ramat-Gan, Israel)                                   16:20 – 16:40

Redox modulation of adjacent thiols in VLA-4 by the immunomodulatory AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state

 

 

Coffee break                                                   16:40 – 17:00

 

 

PLENARY SESSION  9  Selected presentations                  17:00 – 17:50

 

                                                                        Chair: Adit Ben-Baruch (Tel Aviv, Israel)

Chair: Sjoerd H. van der Burg (Leiden, The Netherlands)

 

Tali Feferman (Rechovot, Israel)

Hypoxia restricts CTL-mediated tumor rejection: insights from live intratumoral imaging

 

Cecile Gouttefangeas (Tübingen, Germany)

A new -toll like receptor ligand as strong adjuvant for peptide vaccination

 

TBN

TBN

TBN

 

PLENARY SESSION 10                                                         18:00 – 19:50

Cancer immunotherapy III: Novel approaches and perspectives

 

Chair: Angel Porgador (Beer Sheva, Israel)

Chair: Udo Gaipl (Erlanger, Germany)

 

Jiřina Bartůňková (Prague, Czech Rep)                               18:00 – 18:20

Cell-based immunotherapy for solid tumors

 

Lea Eisenbach (Rehovot, Israel)                                           18:20 – 18:50

Anti-tumor vaccines: simple, sophisticated, combined

Catherine Sautes-Fridman (Paris, France)                          18:50 – 19:20

The functional diversity of intratumoral T cells in clear cell renal cell cancer

 

William J. Murphy (Sacramento, CA, USA)                          19:20 – 19:50

Impact of obesity on T cell exhaustion and effects on immunotherapy

 


April 27, 2017

 

Keynote Presentation                                                           8:30 – 9:15

 

Chair: Luca Vannucci (Prague, Czech Rep)

 

Robert Ferris (Pittsburgh, PA, USA)

Novel immunotherapeutic strategies and combinations to overcome immune escape in head and neck cancer

 

 

PLENARY SESSION 11                                                         9:20 – 11:30

Cancer immunotherapy IV: Novel applications and mechanisms

 

                                                                                    Chair: Federico Garrido (Granada, Spain)

Chair: Qing Yi (Cleveland, OH, USA)

 

Joost J. Oppenheim (Frederick, MD)                                    9:20 – 9:50

Curative immunotherapeutic strategy for the treatment of big CT26 and other tumors in mice

 

Per thor Straten (Herlev, Denmark)                                      9:50 – 10:20

Cancer therapy using T cells and running shoes

 

Sjoerd H. Van der Burg (Leiden, The Netherlands)              10:20 – 10:50

Combination of non-immunogenic cell death inducing chemotherapy and immunotherapy for improved tumor immunity

 

Shimon Slavin (Tel Aviv, Israel)                                            10:50 – 11:10

Innovative immunotherapy for prevention and treatment of relapse following conventional chemotherapy or stem cell transplantation

 

Sebastian Bunk (Tübingen, Germany)                                  11:10 – 11:30

Discovery and validation of TCRs for immunotherapeutic application

 

 

Coffee break                                                   11:30 – 11:50

 

 

PLENARY SESSION 12                                                         11:50 – 14:10

Cancer immunotherapy V: New approaches and rationales

 

Chair: Ron Apte (Beer Sheva, Israel)

Chair: Paul Lehmann (Cleveland, OH, USA)

 

Eitan Yefenof (Jerusalem, Israel)                                          11:50 – 12:20

MicroRNAs as diagnostic and therapeutic tools in leukemia

 

Yona Keisari (Tel Aviv, Israel)                                               12:20 – 12:50

Development of an Integrated Novel Radiotherapy and Immunotherapy cancer treatment: The journey from the pre-clinical to clinical trials

 

Marek Kovář (Prague, Czech Rep)                                        12:50 – 13:10

Complexes of IL-2 and anti-IL-2 mAb in cancer immunotherapy

 

Fabrizio Mattei (Rome, Italy)                                                 13:10 – 13:40

Microfluidic technology as a new tool to investigate cancer and immune cells crosstalk for immunotherapy

 

Lunch break                                        13:40 – 14:30

 

 

PLENARY SESSION  13   Best Abstract presentations         14:30 – 15:20

 

Chair: Mads Andersen (Herlev, Denmark)

Chair: Anahid Jewett (Los Angeles, CA, USA)

 

TBN

TBN

TBN

TBN

TBN

 

 

Coffee break                                                   15:20 – 15:40

 

 

PLENARY SESSION 14                                                         15:40 – 17:50

Cancer immunotherapy VI: New approaches and rationales

 

Chair: Rolf Kiessling (Stockholm, Sweden)

Chair: William Murphy (Sacramento, CA, USA)

 

Angel Porgador (Beer Sheva, Israel)                                    15:40 – 16:10

Natural Killer Immunity and Cancer Immunome

 

Georgi Guruli (Richmond, VA, USA)                                     16:10 – 16:30

Monitoring dendritic cells trafficking in mice using Multi-Spectral Imaging

 

Mansour Haeryfar (London, Ontario, Canada)                      16:30 – 16:50

MAIT Cells in Colorectal Carcinoma: Friend or Foe?

 

Qing Yi (Cleveland, OH, USA)                                               16:50 – 17:20

New T cell subsets for cancer adoptive cell therapy

 

Mads Andersen (Herlev, Denmark)                                       17:20 – 17:50

Anti-regulatory T cells: An alternative approach to target immunosuppressive mechanisms

 

 

CONFERENCE CLOSING: CONCLUDING REMARKS        17:50 – 18:20

 

Anatoli Malyguine

 

Natalia AptsiauriIntroduction to CITIM-2019

_____________________________________________

 

 

Banquet          19:30

 

 














 

 

 

 
   

 

 




1